A non-profit medical research foundation dedicated to finding a treatment or cure for frontotemporal dementia (FTD).
San Francisco, CA
Joined March 2017
- Tweets797
- Following517
- Followers883
- Likes2.2K
Pinned Tweet
335! We thank #NSP participants & their loved ones, participating @allftd investigators & their teams, sponsors, and the many others who made this achievement possible.
The Neurofilament Surveillance Project has met its goal of enrolling 335 participants in its remote blood biomarker study on familial frontotemporal degeneration (#FTLD)! This is an important milestone in our efforts to identify and validate biomarkers for FTLD. @BluefieldProj
Are you attending#ISFTD2026 and want to talk progranulin-related research or therapeutic development, the @BluefieldProj team welcomes the chance to connect.
The Bluefield Project is heading to AFTD's 2026 FTD Research Roundtable (September 23-25, 2026) in Arlington, VA to discuss Biomarker Strategies for FTD Clinical Trials.
We look forward to connecting with attendees advancing progranulin and FTD research.
New workshop hosted by NINDS, NIA and NIAID
Date & time: June 1 & 2, 2026 from 10am to 5pm
Registration link: mregs.nih.gov/ninds/2ba4-225…
A recent @ScienceMagazine article highlights the creation of the @BluefieldProj and progress over 17 years toward therapies for FTD caused by GRN mutations.
🔗 science.org/content/article/…
#FTDResearch #GRN #Progranulin #RareDiseaseResearch #BluefieldProject
𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐃𝐚𝐲 𝐰𝐚𝐬 𝐭𝐡𝐢𝐬 𝐩𝐚𝐬𝐭 𝐰𝐞𝐞𝐤𝐞𝐧𝐝.
Our commitment to progranulin-related #FTD research is year-round.
Awareness is important.
Sustained progress is essential. 💙
#RareDiseaseDay #FTDResearch #CureFTD
Kudos to @Being_Patient_ for this timely coverage of #progranulin (#GRN) FTD and the promising experimental therapeutics being tested in the clinic.
🧬 Mutations in the GRN gene are the most common #genetic cause of frontotemporal dementia (#FTD).
💊 Experimental pills and #gene therapies are vying to be the first to prevent and slow the #disease.
Here's more from @SpichakSimon: beingpatient.com/race-to-tre… 🔗
@BluefieldProj is attending the Gordon Research Conference for #FTD & Related Rare Dementias (Feb 15–20, 2026). Looking forward to connecting with researchers advancing progranulin & FTD science. Attending? Let’s meet. 📩 [email protected]
👉 tinyurl.com/ycxpjt8b
@BluefieldProj to speak at the #FNIH Biomarkers Consortium Symposium (Feb 9–10, Bethesda, MD).
Looking forward to discussions on biomarkers, collaboration, and advancing neurodegenerative disease research—including #FTD.
#Biomarkers #FTDResearch #CureFTD #BluefieldProject
Earlier this week, @EliLillyandCo discontinued investigational gene therapy LY3884963 (PR006) for 𝘎𝘙𝘕-FTD, citing lack of efficacy. Data to be shared at a future meeting.
Thank you to Lilly, Prevail Therapeutics, and trial participants.
#FTDResearch #GRN #CureFTD #CureFTD
Another meaningful way to get involved this year: listening, learning, and staying informed. 🎧 #FTD-focused podcasts and education—like the
@RememberMePodcast,
@AFTD’s Educational Webinars, and
@4theirthoughts' valuable perspectives from families, clinicians, and researchers.
Getting involved doesn’t always start in a lab—it often starts with community. Orgs like @AFTDHope, #CureGRN, @CureMaptFtd , @CurePSP, @End_the_Legacy, #RememberMePodcast and #ForTheirThoughtsFoundation provide vital advocacy, education, and support for families affected by #FTD.
It’s a new year—and a new way to learn about clinical trials. Clinical trials help determine whether new therapies are safe and effective, and participation moves #FTD research forward.
🔬 Explore 𝘎𝘙𝘕 clinical trials:
progranulinnavigator.org/dir…
#FTDResearch #ClinicalTrials #GRN
A new year is a natural time to turn intention into action.
Getting involved in FTD research — joining the @EndFTDregistry, studies like #ALLFTD and #GENFI, and exploring clinical trials helps move potential treatments forward.
🔗 progranulinnavigator.org/dir…
Attending the #JPM2026 Healthcare Conference next week?
If you’re working in #FTDResearch or therapeutic development, the Bluefield Project team would welcome the chance to connect.
📩 [email protected]
#JPMHealthcare #Biotech #Neurodegeneration #CureFTD
A new year doesn’t reset the work - it carries it forward. Progress is built over time through collaboration and sustained commitment. Our focus remains unchanged: advancing FTD research, together.
Happy New Year! - The Bluefield Team
📚📷 2025 Research Spotlight: Q4 Bluefield-supported Q4 publications advanced #FTDResearch across biomarkers, brain structure, and functional networks—strengthening diagnosis and disease tracking. This post wraps up our 2025 Year-End Research series. 📷💙
❄️ This holiday season, we’re grateful for the researchers, clinicians & collaborators advancing FTD science. Progress happens through collaboration. Wishing you a peaceful holiday season.
#FTDResearch #CureFTD #BluefieldProject
📚🔬 2025 Research Spotlight: Q3
Bluefield-supported Q3 publications advanced #FTD research across molecular mechanisms, biomarkers, brain connectivity + global risk factors—from cellular biology to population-level insights. Proud to support this science. 💙
#FTDResearch
📚🔬 𝟐𝟎𝟐𝟓 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐐𝟐
Q2: The Bluefield Project-supported publications advanced FTD research across genetics, biomarkers, proteomics, digital health, and disease models—moving the field closer to treatments 💙
#FTDResearch #CureFTD
🔬𝟐𝟎𝟐𝟓 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐐𝟏
Highlighting early 2025 publications supported by #TheBluefieldProject—advancing imaging, biomarkers, inflammation research, and cognitive screening in FTD. Proud to support science moving this field forward. 💙 #FTDResearch